常見問題

A:

  1. It is necessary to ensure that a monitoring device with the letter ‘L’ is inserted into the left chest position of the underwear, and that the metal probe of the device is in close contact with the skin surface.
  2. It is necessary to ensure that a monitoring device with the letter ‘R’ is inserted into the right chest position of the underwear, and that the metal probe of the device is in close contact with the skin surface.
  3. Raise your arms three times consecutively to check if the Breast biorhythm monitoring device underwear has shifted. At the same time, check if the distance between the silver detection point and the nipple is within 1cm. If so, it means the sensor is in good contact with the skin, and you can proceed with the monitoring.

A:

  1. Strictly follow the instructions for monitoring.
  2. The 2-6 days after the start of menstruation is the most stable period for female hormone levels, and the test data will be more accurate.
  3. Daytime testing is to ensure the completeness of the data; nighttime testing is for the accuracy of the data.

A :

Women aged 20 and above.
Users who should contact customer service before using the device include:

  1. Patients with suspected breast cancer who have undergone breast fluid cytology pathology examination.
  2. Patients with suspected breast cancer who have undergone core needle biopsy (CNB).
  3. Patients who have only undergone chemotherapy for breast diseases.

A:

Temporarily not suitable:

  1. Those who have had breast surgery and the wound has not healed yet.
  2. Those with mastitis during lactation who have not recovered.
  3. Those with various traumatic, erosive, or unhealed epidermal ulcers on the breast.

Long-term not suitable:

  1. Those who have undergone radiation therapy for breast diseases.
  2. Those who have undergone breast removal surgery for breast diseases.
  3. Those who have undergone corrective surgery for breast deformities.
  4. Those who have received breast cosmetic or reconstruction surgery with injected or implanted fillers.”

A: The monitoring is required to be continuous for 8 hours, and the report will be generated within 48 hours.

A: It will not affect the monitoring results, but it will impact the battery life of the device.

A: When the breast monitoring device is flashing red and cannot be detected by the system, it means the battery needs to be replaced.

A: No. Each breast monitoring device represents one account and one set of tracking records, so it can only be paired with one mobile phone. If you want to switch to a new phone, you need to first unpair the device from the original phone, and then pair it with the new phone.

A:

  1. Ensure your phone is within 1 meter of the breast monitoring device, then gently press the button on the back of the device to activate Bluetooth.

  2. Ensure the device battery has sufficient charge. If the battery is depleted, replace it with a new one.

  3. Ensure the device is not already paired with another phone. If it is paired with another phone, use that phone’s app to unpair the device first.

  4. Try restarting your phone and make sure Bluetooth is enabled before attempting to pair.

A: Yes, you do need to turn on your phone and Bluetooth to start and stop the monitoring, connect the device, and upload the data. However, during the monitoring process itself, you do not need to keep your phone constantly turned on and connected. You can exit the app and turn off your phone at any time.

A: When pairing, please ensure your phone and the breast monitoring device are within 1 meter of each other. If you still cannot pair them, please contact customer service.

A: Yes, you can bring the breast monitoring device on a plane.

A: The breast monitoring device is not waterproof. Please be careful to avoid water contact. If the device gets wet, it can cause a short circuit in the electronic circuits and affect the normal functioning of the device.

A: After completing the monitoring, please connect your phone with the breast monitoring device (left and right) to allow the data synchronization process, which will take approximately 1 minute.

A: After the data synchronization is complete, please turn off the breast monitoring device to preserve the battery life. The breast monitoring device cannot get wet, so before washing your undergarments, please make sure the device has been removed.

A: We do not recommend monitoring while exercising, as the changes in your body environment may affect the accuracy of the data collected by the device.

A: Sweating can have a slight impact on the monitoring, but it will not affect the accuracy of the data.

A: We do not recommend using the monitoring device during your menstrual period or pregnancy, as your biological rhythms can undergo changes during those periods, which may affect the accuracy of the monitoring.

A: Breast monitoring devices are safe for human use, have offline data caching capabilities, and transmit rhythm data only through low-power medical-grade Bluetooth. Therefore, they have no impact on pregnant women. However, due to differences in the biological rhythms of pregnant women, we do not recommend using them during pregnancy.

A: It is suitable for use if you have been diagnosed with a benign breast tumor. However, if you have undergone radiation therapy on the breast, it is not recommended to use a breast monitorig device. If you have undergone chemotherapy, please contact customer service before using the device. (Note: If you have undergone chemotherapy or radiation therapy but have ensured that it has not affected any changes in breast tissue, it is permissible to use the device.)

A: If you have any usage-related issues, please call our customer service hotline at +852 3690 9862.

A: The product has obtained multiple core patents and is certified with the CE mark, which ensures compliance with European electronic product safety standards. The product also does not emit electrical currents into the user’s body, making it very safe to use.

A: The development of major breast diseases is not an overnight occurrence. This system monitors changes in breast health and provides risk level indications based on these changes. When the risk level reaches 4-5, it is recommended for users to promptly seek medical examination at a healthcare facility. Early utilization of the system increases the chances of early detection of major breast diseases.

A: According to research from the Nobel Prize in Physiology or Medicine and the National Institutes of Health (NIH), the body temperature rhythm is indeed a biological marker. This detection system has undergone rigorous clinical trials and has shown a high sensitivity of 97.7% and an accuracy rate of 85.9% compared to biopsy.

A:

  1. Whether the device is worn in the correct position.
  2. Whether the device is worn for a sufficient duration of time.
  3. Whether the device is used according to the recommended optimal monitoring time stated in the instructions.

A:

  1. Due to the influence of different environments on individual biological rhythms, it is recommended that during the initial period of wearing, the duration of a single monitoring session should not be less than 8 hours in order to establish more comprehensive basic data of personal biological rhythms.
  2. When wearing, it is necessary to strictly distinguish between left and right devices and ensure that the sensor probe is closely adhered to the skin.
  3. For users who require focused monitoring, it is recommended to follow the system prompts and receive guidance from professional customer services to conduct monitoring during the following period (optimal monitoring period):

For users who have not yet reached menopause, please perform the monitoring on days 2-6 after each menstrual cycle.

For peri-menopausal and post-menopausal users, choose a fixed time period each month to perform the monitoring.

A: We categorize them into five levels based on the fluctuations in the individual’s body’s biological rhythm waveform.

The following is just an example:

Level 0: Incomplete or invalid data.

Level 1: Normal waveform fluctuations in the current monitoring session. The rhythm disparity between the left and right breasts is at Level 1. Monthly monitoring is recommended.

Level 2: No significant abnormalities in the waveform observed in the current monitoring session. The rhythm disparity between the left and right breasts is at Level 2. Monthly monitoring is recommended, with a focus on the rhythm fluctuations between the left and right breasts.

Level 3: Mild abnormalities in the waveform observed in the current monitoring session. The rhythm disparity between the left and right breasts is at Level 3. It is recommended to conduct two additional monitoring sessions, paying attention to the rhythm fluctuations between the left and right breasts. If the correct method is followed and the disparity remains at Level 3 for two consecutive sessions, it is advisable to refer to a medical examination report within 4-6 months.

Level 4: Prolonged mild abnormalities in the waveform observed in the current monitoring session. The rhythm disparity between the left and right breasts is at Level 4. It is recommended to continue monitoring twice within the same month, with each session lasting a full 24 hours. If both consecutive monitoring sessions indicate Level 4 and there has been no medical examination within 3 months, it is advised to consult a professional doctor in the near future.

Level 5: Noticeable and persistent mild abnormalities in the waveform observed in the current monitoring session. The rhythm disparity between the left and right breasts is at Level 5. It is recommended to conduct three consecutive monitoring sessions within the same month, with each session lasting a full 24 hours. If all three consecutive sessions indicate Level 5 and there has been no medical examination within 3 months, it is advised to promptly visit a hospital for further evaluation.

A: Our risk level is not directly related to the grading of breast fibrocystic changes. Breast fibrocystic changes and the risk level of our product are two different concepts and systems. The grading of breast fibrocystic changes is based on diagnostic methods such as ultrasound, magnetic resonance imaging, or other examinations conducted at a hospital. On the other hand, our risk level is determined based on dynamic collection of body temperature, humidity rhythm changes, and other principles to provide risk alerts for breast health conditions. We recommend seeking medical assistance when there are significant rhythmic changes indicating high risk.

A: Yes, the breast monitoring device cannot replace examinations conducted in medical institutions. It is simply an additional tool for early detection of breast cancer in home settings.